<DOC>
	<DOCNO>NCT00924573</DOCNO>
	<brief_summary>Primary objective study confirm efficacy HOE490 O ( glimepiride/metformin ) compare placebo top glimepiride HbA1c change . Secondary objective study evaluate safety HOE490 O ( glimepiride/metformin ) compare placebo top glimepiride well efficacy parameter</brief_summary>
	<brief_title>Comparative Study HOE490 O ( Glimepiride Metformin ) Compared With Placebo Top Glimepiride</brief_title>
	<detailed_description>Patients treat 2-6mg/day glimepiride recruit . The study period consist screen phase 6 week double-blinded phase 24 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 Diabetes Mellitus patient treat constant dose glimepiride top diet exercise Patients give inform consent participate study Patients HbA1c &lt; 7.0 % &gt; 11.0 % Patients follow laboratory test abnormality : ALT and/or AST : &gt; 3 X ULN Neutrophils : &lt; 1,000/mm3 and/or platelet &lt; 100,000/mm3 Hemoglobin : &lt; 11 g/dL Creatinine : &gt; = 1.3 mg/dL case male &gt; = 1.0 mg/dL case female The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Glimepiride</keyword>
	<keyword>Metformin</keyword>
	<keyword>Combination Drug Therapy</keyword>
</DOC>